BridgeBio Oncology Therapeutics’ (BBOT) “Outperform” Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of BridgeBio Oncology Therapeutics (NASDAQ:BBOT) in a research note released on Wednesday,Benzinga reports. The firm currently has a $25.00 price objective on the stock.

A number of other research analysts have also commented on the stock. Wall Street Zen upgraded shares of BridgeBio Oncology Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 18th. JPMorgan Chase & Co. cut their price objective on shares of BridgeBio Oncology Therapeutics from $27.00 to $25.00 and set an “overweight” rating for the company in a research report on Friday, August 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BridgeBio Oncology Therapeutics in a research report on Thursday, June 18th. UBS Group lowered BridgeBio Oncology Therapeutics to an “overweight” rating in a research note on Wednesday, July 8th. Finally, Oppenheimer began coverage on BridgeBio Oncology Therapeutics in a report on Monday, June 22nd. They set an “outperform” rating and a $22.00 price target for the company. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.88.

BridgeBio Oncology Therapeutics Price Performance

Shares of BridgeBio Oncology Therapeutics stock opened at $4.95 on Wednesday. The business has a fifty day simple moving average of $8.66 and a two-hundred day simple moving average of $8.67. BridgeBio Oncology Therapeutics has a 1 year low of $4.90 and a 1 year high of $14.87. The company has a market capitalization of $396.84 million, a price-to-earnings ratio of -1.79 and a beta of 0.38.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($705.20) EPS for the quarter. As a group, equities analysts anticipate that BridgeBio Oncology Therapeutics will post -2.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Paradigm Biocapital Advisors LP increased its holdings in shares of BridgeBio Oncology Therapeutics by 21.2% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 2,261,749 shares of the company’s stock worth $28,317,000 after purchasing an additional 395,608 shares during the period. Laurion Capital Management LP boosted its stake in shares of BridgeBio Oncology Therapeutics by 40.1% in the fourth quarter. Laurion Capital Management LP now owns 1,464,938 shares of the company’s stock valued at $18,341,000 after buying an additional 419,138 shares during the period. Armistice Capital LLC grew its position in BridgeBio Oncology Therapeutics by 142.7% during the fourth quarter. Armistice Capital LLC now owns 1,000,000 shares of the company’s stock worth $12,520,000 after buying an additional 588,000 shares in the last quarter. Opaleye Management Inc. increased its stake in BridgeBio Oncology Therapeutics by 1,213.8% during the 2nd quarter. Opaleye Management Inc. now owns 700,000 shares of the company’s stock worth $5,334,000 after acquiring an additional 646,718 shares during the period. Finally, Geode Capital Management LLC increased its stake in BridgeBio Oncology Therapeutics by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 561,987 shares of the company’s stock worth $7,039,000 after acquiring an additional 20,385 shares during the period. Institutional investors and hedge funds own 54.89% of the company’s stock.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.